282 related articles for article (PubMed ID: 24720805)
1. Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes.
Sawyer L; Azorin JM; Chang S; Rinciog C; Guiraud-Diawara A; Marre C; Hansen K
J Med Econ; 2014 Jul; 17(7):508-19. PubMed ID: 24720805
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of asenapine in the treatment of patients with bipolar I disorder with mixed episodes in an Italian context.
Caresano C; Di Sciascio G; Fagiolini A; Maina G; Perugi G; Ripellino C; Vampini C
Adv Ther; 2014 Aug; 31(8):873-90. PubMed ID: 25055791
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada.
Lachaine J; Beauchemin C; Mathurin K; Gilbert D; Beillat M
BMC Psychiatry; 2014 Jan; 14():16. PubMed ID: 24450548
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder.
Calvert NW; Burch SP; Fu AZ; Reeves P; Thompson TR
J Manag Care Pharm; 2006 May; 12(4):322-30. PubMed ID: 16792438
[TBL] [Abstract][Full Text] [Related]
5. Asenapine: a review of its use in the management of mania in adults with bipolar I disorder.
Chwieduk CM; Scott LJ
CNS Drugs; 2011 Mar; 25(3):251-67. PubMed ID: 21323396
[TBL] [Abstract][Full Text] [Related]
6. Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials.
Szegedi A; Zhao J; van Willigenburg A; Nations KR; Mackle M; Panagides J
BMC Psychiatry; 2011 Jun; 11():101. PubMed ID: 21689438
[TBL] [Abstract][Full Text] [Related]
7. Effects of asenapine in bipolar I patients meeting proxy criteria for moderate-to-severe mixed major depressive episodes: a post hoc analysis.
Berk M; Tiller JW; Zhao J; Yatham LN; Malhi GS; Weiller E
J Clin Psychiatry; 2015 Jun; 76(6):728-34. PubMed ID: 25612216
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode.
Ekman M; Lindgren P; Miltenburger C; Meier G; Locklear JC; Chatterton ML
Pharmacoeconomics; 2012 Jun; 30(6):513-30. PubMed ID: 22591130
[TBL] [Abstract][Full Text] [Related]
9. A Review of Asenapine in the Treatment of Bipolar Disorder.
Vieta E; Montes JM
Clin Drug Investig; 2018 Feb; 38(2):87-99. PubMed ID: 29067671
[TBL] [Abstract][Full Text] [Related]
10. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study.
McIntyre RS; Cohen M; Zhao J; Alphs L; Macek TA; Panagides J
J Affect Disord; 2010 Nov; 126(3):358-65. PubMed ID: 20537396
[TBL] [Abstract][Full Text] [Related]
11. Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses.
Azorin JM; Sapin C; Weiller E
J Affect Disord; 2013 Feb; 145(1):62-9. PubMed ID: 22868059
[TBL] [Abstract][Full Text] [Related]
12. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of asenapine for acute mania in bipolar I disorder: meta-analyses of randomized-controlled trials.
Vita A; De Peri L; Siracusano A; Sacchetti E;
Int Clin Psychopharmacol; 2013 Sep; 28(5):219-27. PubMed ID: 23719049
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Asenapine Versus Olanzapine in Combination With Divalproex for Acute Mania: A Randomized Controlled Trial.
Mahajan V; Arora M; Tandon VR; Gillani Z; Praharaj SK
J Clin Psychopharmacol; 2019; 39(4):305-311. PubMed ID: 31205195
[TBL] [Abstract][Full Text] [Related]
15. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
McIntyre RS; Cohen M; Zhao J; Alphs L; Macek TA; Panagides J
J Affect Disord; 2010 Apr; 122(1-2):27-38. PubMed ID: 20096936
[TBL] [Abstract][Full Text] [Related]
16. A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder.
Bridle C; Palmer S; Bagnall AM; Darba J; Duffy S; Sculpher M; Riemsma R
Health Technol Assess; 2004 May; 8(19):iii-iv, 1-187. PubMed ID: 15147609
[TBL] [Abstract][Full Text] [Related]
17. Asenapine treatment and health-related quality of life in patients experiencing bipolar I disorder with mixed episodes: post-hoc analyses of pivotal trials.
Michalak EE; Guiraud-Diawara A; Sapin C
Curr Med Res Opin; 2014 Apr; 30(4):711-8. PubMed ID: 24329543
[TBL] [Abstract][Full Text] [Related]
18. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states.
McIntyre RS; Cohen M; Zhao J; Alphs L; Macek TA; Panagides J
Bipolar Disord; 2009 Nov; 11(7):673-86. PubMed ID: 19839993
[TBL] [Abstract][Full Text] [Related]
19. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder.
Soares-Weiser K; Bravo Vergel Y; Beynon S; Dunn G; Barbieri M; Duffy S; Geddes J; Gilbody S; Palmer S; Woolacott N
Health Technol Assess; 2007 Oct; 11(39):iii-iv, ix-206. PubMed ID: 17903393
[TBL] [Abstract][Full Text] [Related]
20. Asenapine versus olanzapine in acute mania: a double-blind extension study.
McIntyre RS; Cohen M; Zhao J; Alphs L; Macek TA; Panagides J
Bipolar Disord; 2009 Dec; 11(8):815-26. PubMed ID: 19832806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
